Epithelial–Mesenchymal Transition Suppression by ML210 Enhances Gemcitabine Anti-Tumor Effects on PDAC Cells
Biomolecules · 2025
DOI: 10.3390/biom15010070 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, 2025. Verfasst von Keisuke Takemura und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan. Hauptthemen laut MEDLINE: Deoxycytidine, Epithelial-Mesenchymal Transition, Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development, Matsushima Holdings Co., Ltd..
Abstract (Originalsprache)
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers in the world. Neoadjuvant chemotherapy (NAC) has become a standard treatment for patients scheduled for surgical resection, but the high rate of postoperative recurrence is a critical problem. Optimization of NAC is desirable to reduce postoperative recurrence and achieve long-term survival. However, if a patient’s general condition deteriorates due to NAC toxicity, surgical outcomes may be compromised. Therefore, we aimed to identify drug(s) that can be used in combination with gemcitabine (GEM), a drug widely used for the treatment of PDAC, to inhibit distant metastatic recurrence, particularly after surgery. After several screening steps, ML210, a low molecular weight chemical, was found to suppress the epithelial–mesenchymal transition (EMT) in PDAC cells in combination with GEM. Specifically, low dose ML210 in combination with GEM was sufficient for cell migration without apparent toxicity or cell death. Mechanistically, ML210, which was developed as a glutathione peroxidase 4 (GPX4) inhibitor to induce lipid peroxidation, increased the oxidized lipid concentrations in PDAC cells. The oxidization of the cell membrane lipids may suppress EMT, including cell migration. Since EMT is a major malignant phenotype of PDAC, our findings may lead to the advancement of PDAC therapy, especially in the prevention of postoperative recurrence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan.
- Department of Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan.
- Saiseikai Shiga Hospital, 2-4-1 Ohashi, Ritto 520-3046, Shiga, Japan.
- Fukuchiyama City Hospital, 231 Atsunaka-cho, Fukuchiyama 620-8505, Kyoto, Japan.
ORCID-Profile: Hiroaki Yasuda, Kazumi Iwata, Yoshito Itoh
Förderung
- Japan Agency for Medical Research and Development
- Matsushima Holdings Co., Ltd.
Zitieren
APA
Takemura, K., Ikeda, K., Miyake, H., Sogame, Y., Yasuda, H., Okada, N., Iwata, K., Sakagami, J., Yamaguchi, K., Itoh, Y., & Umemura, A. (2025). Epithelial–Mesenchymal Transition Suppression by ML210 Enhances Gemcitabine Anti-Tumor Effects on PDAC Cells. Biomolecules. https://doi.org/10.3390/biom15010070
Vancouver
Takemura K, Ikeda K, Miyake H, Sogame Y, Yasuda H, Okada N, et al. Epithelial–Mesenchymal Transition Suppression by ML210 Enhances Gemcitabine Anti-Tumor Effects on PDAC Cells. Biomolecules. 2025. doi:10.3390/biom15010070
BibTeX
@article{Takemura2025,
author = {Takemura, Keisuke and Ikeda, Kyohei and Miyake, Hayato and Sogame, Yoshio and Yasuda, Hiroaki and Okada, Nobuhiro and Iwata, Kazumi and Sakagami, Junichi and Yamaguchi, Kanji and Itoh, Yoshito and Umemura, Atsushi},
title = {Epithelial–Mesenchymal Transition Suppression by ML210 Enhances Gemcitabine Anti-Tumor Effects on PDAC Cells},
journal = {Biomolecules},
year = {2025},
doi = {10.3390/biom15010070}
}
EUVIMED